Cargando…

Forced Expiratory Flow (FEF(25–75%)) as a Clinical Endpoint in Children and Adolescents with Symptomatic Asthma Receiving Tiotropium: A Post Hoc Analysis

INTRODUCTION: In pediatric patients with asthma, measurements of forced expiratory volume in 1 s (FEV(1)) may be normal or may not correlate with symptom severity. Forced expiratory flow at 25–75% of the vital capacity (FEF(25–75%)) is a potentially more sensitive parameter for assessing peripheral...

Descripción completa

Detalles Bibliográficos
Autores principales:	Szefler, Stanley J., Goldstein, Stanley, Vogelberg, Christian, Bensch, George W., Given, John, Jugovic, Branko, Engel, Michael, Moroni-Zentgraf, Petra M., Sigmund, Ralf, Hamelmann, Eckard H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer Healthcare 2020
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7672130/ https://www.ncbi.nlm.nih.gov/pubmed/32399899 http://dx.doi.org/10.1007/s41030-020-00117-6

Ejemplares similares

A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Erratum to: A randomised dose-ranging study of tiotropium Respimat® in children with symptomatic asthma despite inhaled corticosteroids
por: Vogelberg, Christian, et al.
Publicado: (2015)

Efficacy and Safety of Tiotropium in Children and Adolescents
por: Hamelmann, Eckard, et al.
Publicado: (2018)

Commentary: Treating Pediatric Asthma According Guidelines
por: Szefler, Stanley, et al.
Publicado: (2019)

Tiotropium add-on therapy is safe and reduces seasonal worsening in paediatric asthma patients
por: Vogelberg, Christian, et al.
Publicado: (2019)

Comparative Responses in Lung Function Measurements with Tiotropium in Adolescents and Adults, and Across Asthma Severities: A Post Hoc Analysis
por: Halpin, David M. G., et al.
Publicado: (2020)

A randomised controlled trial of tiotropium in adolescents with severe symptomatic asthma
por: Hamelmann, Eckard, et al.
Publicado: (2017)

A comparison of tiotropium, long-acting β(2)-agonists and leukotriene receptor antagonists on lung function and exacerbations in paediatric patients with asthma
por: Vogelberg, Christian, et al.
Publicado: (2020)

Asthma exacerbations and worsenings in patients aged 1–75 years with add-on tiotropium treatment
por: Mark FitzGerald, J., et al.
Publicado: (2020)

O05 - Once-daily tiotropium in adolescents with symptomatic asthma despite inhaled corticosteroid treatment: a dose-ranging study
por: Vogelberg, Christian, et al.
Publicado: (2014)

Higher BMI is associated with higher expiratory airflow normalised for lung volume (FEF25–75/FVC) in COPD
por: Abston, Eric, et al.
Publicado: (2017)

Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium
por: Hamelmann, Eckard
Publicado: (2018)

Corrigendum to “Managing Severe Asthma: A Role for the Long-Acting Muscarinic Antagonist Tiotropium”
por: Hamelmann, Eckard
Publicado: (2019)

Peak expiratory flow as an endpoint for clinical trials in asthma: a comparison with FEV(1)
por: Halpin, David M. G., et al.
Publicado: (2019)

The Usefulness of FEF(25–75) in Predicting Airway Hyperresponsiveness to Mannitol
por: Kim, Youlim, et al.
Publicado: (2021)

Clinical Implications of Having Reduced Mid Forced Expiratory Flow Rates (FEF(25-75)), Independently of FEV1, in Adult Patients with Asthma
por: Riley, Craig M., et al.
Publicado: (2015)

Addressing the risk domain in the long‐term management of pediatric asthma
por: Hamelmann, Eckard, et al.
Publicado: (2019)

Inflammation Markers and FEF(25-75): A Relevant Link in Children With Asthma
por: Tosca, Maria Angela, et al.
Publicado: (2016)

Role of FEF(25-75) in managing children with newly-diagnosed asthma in clinical practice
por: Tosca, Maria A., et al.
Publicado: (2022)

Tiotropium Respimat® in asthma: a double-blind, randomised, dose-ranging study in adult patients with moderate asthma
por: Beeh, Kai-Michael, et al.
Publicado: (2014)

Tiotropium in the add-on treatment of asthma in adults: clinical trial evidence and experience
por: Vogelberg, Christian
Publicado: (2016)

Pharmacodynamics and Pharmacokinetics Following Once-Daily and Twice-Daily Dosing of Tiotropium Respimat(®) in Asthma Using Standardized Sample-Contamination Avoidance
por: Beeh, Kai-Michael, et al.
Publicado: (2016)

Association of parental FEF25-75% during a methacholine challenge and children's PC20 and diagnosis of asthma
por: Houlbrook, D, et al.
Publicado: (2010)

Asthma diagnosis and treatment – 1002. FEF25-75%: a more sensitive indicator in the early detection of asthma
por: Tavakol, Marzieh, et al.
Publicado: (2013)

Value of Exhaled Nitric Oxide and FEF(25–75) in Identifying Factors Associated With Chronic Cough in Allergic Rhinitis
por: Liu, Xiaofang, et al.
Publicado: (2019)

FEF(25-75%) Values in Patients with Normal Lung Function Can Predict the Development of Chronic Obstructive Pulmonary Disease
por: Kwon, Do Sun, et al.
Publicado: (2020)

Correlation between Reduced FEF25-75% and a Positive Methacholine Challenge Test in Adults with Nonobstructive Baseline Spirometry
por: Shafiq, Irfan, et al.
Publicado: (2021)

Effect of tiotropium on health-related quality of life as a primary efficacy endpoint in COPD
por: Tonnel, A-B, et al.
Publicado: (2008)

Tiotropium respimat(®) add-on therapy reduces airflow obstruction in patients with symptomatic moderate asthma, independent of T(H)2 inflammatory status
por: Yang, WH, et al.
Publicado: (2014)

Evidence vs. efficacy in allergen-specific immunotherapy: Considerations using the example of tradable products in Germany
por: Brehler, Randolf, et al.
Publicado: (2016)

Comparing LAMA with LABA and LTRA as add-on therapies in primary care asthma management
por: Kaplan, Alan, et al.
Publicado: (2020)

Long-Term Once-Daily Tiotropium Respimat® Is Well Tolerated and Maintains Efficacy over 52 Weeks in Patients with Symptomatic Asthma in Japan: A Randomised, Placebo-Controlled Study
por: Ohta, Ken, et al.
Publicado: (2015)

Cost-Effectiveness Of The SQ(®) Grass SLIT-Tablet In Children With Allergic Rhinitis: A German Payer Perspective
por: Vogelberg, Christian, et al.
Publicado: (2019)

Testing Two Different Doses of Tiotropium Respimat® in Cystic Fibrosis: Phase 2 Randomized Trial Results
por: Bradley, Judy M., et al.
Publicado: (2014)

Tiotropium/Olodaterol Delays Clinically Important Deterioration Compared with Tiotropium Monotherapy in Patients with Early COPD: a Post Hoc Analysis of the TONADO(®) Trials
por: Rabe, Klaus F., et al.
Publicado: (2020)

FEF Excitability in Attentional Bias: A TMS-EEG Study
por: Torriero, Sara, et al.
Publicado: (2019)

Allergen immunotherapy during the COVID‐19 pandemic—A survey of the German Society for Allergy and Clinical Immunology
por: Pfaar, Oliver, et al.
Publicado: (2022)

Tiotropium and Salmeterol in COPD Patients at Risk of Exacerbations: A Post Hoc Analysis from POET-COPD(®)
por: Vogelmeier, Claus F., et al.
Publicado: (2015)

Effect of tiotropium/olodaterol on sedentary and active time in patients with COPD: post hoc analysis of the VESUTO(®) study
por: Minakata, Yoshiaki, et al.
Publicado: (2019)

Contribution of FEF to Attentional Periodicity during Visual Search: A TMS Study
por: Dugué, Laura, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_jr6q0r1gtvg88d4s6em2eca7e8